<DOC>
	<DOCNO>NCT00734162</DOCNO>
	<brief_summary>The primary purpose study evaluate effectiveness , safety , tolerability tenofovir disoproxil fumarate ( TDF ) adolescent ( age 12-17 year ) chronic hepatitis B virus ( HBV ) infection . The optimal treatment adolescent chronic HBV infection currently unknown . Treatment interferon alfa , lamivudine , adefovir dipivoxil pediatric population show less optimal . Further , safety efficacy entecavir telbivudine establish patient &lt; 16 year age . A study evaluate TDF adolescent ( age 12-17 ) need assess safety efficacy agent treatment chronic hepatitis B patient population . In addition , study help elucidate pharmacokinetic ( PK ) resistance profile TDF . Through participation , study participant help generate critical new information help guide optimal treatment chronic HBV infection adolescent . This randomized , double-blind study evaluate antiviral efficacy , safety , tolerability TDF versus placebo adolescent chronic HBV infection . TDF treatment-naive participant randomize 1:1 ratio TDF placebo . After 72 week blind treatment , participant switch open-label TDF additional 2.5 year treatment , provide safety concern identify Independent Data Monitoring Committee monitoring study .</brief_summary>
	<brief_title>Evaluation Tenofovir Disoproxil Fumarate Adolescents With Chronic Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion Criteria Male female , 12 17 year age , inclusive ( consent parent/legal guardian require ) Documented chronic HBV infection HBeAg positive HBeAg negative Weight &gt; 35 kg Able swallow oral tablet HBV DNA &gt; 100,000 copies/mL ( polymerase chain reaction ( PCR ) method ) Alanine aminotransferase ( ALT ) &gt; 2 × upper limit normal ( ULN ) screening , OR history ALT &gt; 2 × ULN past 24 month Willing able provide write informed consent/assent ( child parent/legal guardian ) Negative serum pregnancy test ( postmenarchal female ) Estimated glomerular filtration rate ( creatinine clearance [ use Schwartz formula ] ) &gt; 80 mL/min/1.73m^2 Adequate hematologic function ( absolute neutrophil count ≥ 1,500/mm^3 ; hemoglobin ≥ 10.0 g/dL ) No prior TDF therapy ( participant may receive prior interferon oral antiHBV nucleoside/nucleotide therapy ; participant must discontinue interferon therapy ≥ 6 month prior screen ; participant experience antiHBV nucleoside/nucleotide therapy must discontinue therapy ≥ 16 week prior screen avoid flare randomize placebo arm ) Exclusion Criteria Pregnant woman , woman breast feed believe may wish become pregnant course study Males females reproductive potential willing use effective method contraception study Decompensated liver disease Receipt interferon ( pegylated ) therapy within 6 month Screening Visit Receipt antiHBV nucleoside/nucleotide therapy within 16 week Screening Visit Alpha fetoprotein &gt; 50 ng/mL Evidence hepatocellular carcinoma ( HCC ) Coinfection HIV , hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) History significant renal disease ( eg , nephrotic syndrome , renal dysgenesis , polycystic kidney disease , congenital nephrosis , acute tubular necrosis , renal disease ) History significant bone disease ( eg , osteomalacia , chronic osteomyelitis , osteogenesis imperfecta , osteochondroses , multiple bone fracture ) Significant cardiovascular , pulmonary , neurological disease Evidence gastrointestinal malabsorption syndrome may interfere absorption orally administer medication History solid organ bone marrow transplantation Ongoing therapy nephrotoxic agent , competitor renal excretion , systemic chemotherapeutic agent , systemic corticosteroid , interleukin2 ( IL2 ) , immunomodulating investigational agent Known hypersensitivity study drug , metabolite formulation excipients Any condition ( include alcohol substance abuse ) prior therapy , opinion Investigator , would make participant unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>tenofovir</keyword>
	<keyword>adolescent</keyword>
	<keyword>chronic hepatitis B</keyword>
</DOC>